Glucose metabolism continuous deteriorating in male patients with human immunodeficiency virus accepted antiretroviral therapy for 156 weeks

Table 1 Baseline information of human immune deficiency virus-infected male patients (n = 61)

Viable	Total (n = 61)		NGT (n = 50)
	mean ± SD or case (%)	Range	mean ± SD or case (%)	Range
Age (yr)	32.05 ± 8.38	20-58	31.93 ± 8.59	20-60
Infection duration (mo)	11.16 ± 1.19	1-86	11.16 ± 1.19	1-86
T lymphocyte subsets
CD3+ (cells/μL)	1433.98 ± 595.35	470-3074	1489.7 ± 603.75	561-3202
CD3+CD4+ (cells/μL)	313.87 ± 118.473	54-499	324.74 ± 150.37	10-833
CD3+CD4+% (%)	19.78 ± 6.83	1.4-43.4	20.46 ± 8.25	1.4-56.8
CD3+CD8+ (cells/μL)	1119.70 ± 605.0	360-2456	1100.70 ± 498.72	440-2456
CD3+CD8+% (%)	69.97 ± 13.80	36.1-97.2	69.31 ± 14.72	35.8-97.2
1Virus load of HIVRNA	41772.77 ± 10.38	895.0-505987.0	91126.14 ± 2.64	895-970103
Glycose metabolic parameters
FPG (mmol/L)	5.50 ± 0.508	3.90-6.53	5.39 ± 0.40	3.9-6.0
HbA1c (%)	5.35 ± 0.34	4.5-6.2	5.25 ± 0.37	4.1-6.2
FINS (mIU/L)	4.55 ± 3.03	0.5-11.09	2.39 ± 1.16	0.5-10.24
HOMA-IR(mIU × mmol/L2)	1.30 ± 0.84	0.81-2.31	1.21 ± 0.17	0.81-1.74
HOMA-β (mIU/mmol)	52.37 ± 36.25	14.8-182.46	64.10 ± 8.44	30.8-182.46

¹Refers to logarithmic transformation before statistical analysis for nonnormally distributed data. FPG: Fasting plasma glucose; HbA1c: Glycosylated hemoglobin; FINS: Fasting insulin; HOMA-IR: Homeostasis model assessment of insulin resistance; HOMA-β: Homeostasis model assessment of β cells; NGT: Normal glucose tolerance; HIVRNA: Human immune deficiency virus viral nucleic acid.